| Literature DB >> 31410033 |
Muhammad Shafiq1, Jinhu Huang1, Sadeeq Ur Rahman2, Jan Mohammad Shah1, Li Chen1, Yi Gao1, Mengli Wang1, Liping Wang1.
Abstract
PURPOSE: The coexistence of mobile colistin (COL)-resistant gene mcr-1 with extended-spectrum beta-lactamase (ESBL) gene in Escherichia coli has become a serious threat globally. The aim of this study was to investigate the increasing resistance to COL and in particular its coexistence with ESBL-producing E. coli recovered from pig farms in China.Entities:
Keywords: E. coli; ESBL; coexistence; colistin; mcr-1
Year: 2019 PMID: 31410033 PMCID: PMC6643958 DOI: 10.2147/IDR.S209473
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
PCR primers and conditions used in this study
| Primer name | PCR target | Sequence (5′- 3′) | Annealing temperature(°C) | Product size (bp) | Reference |
|---|---|---|---|---|---|
| UAL | TGGTAATTACCGACGAAAACG GC | 62 | 147 | ||
| CTX-MA | CGC TTT GCG ATG TGC AG | 54 | 550 | ||
| SHV-F | GGG TTA TTC TTA TTT GTC GC | 58 | 930 | ||
| TEM-F | ATA AAA TTC TTG AAG ACG AAA | 56 | 1086 | ||
| CLR5-F | CGG TCA GTC CGT TTG TTC | 58 | 309 | ||
| MCR-2-F | TGT TGC TTG TGC CGA TTG GA | 58 | 567 | ||
| MCR-3-F | TTG GCA CTG TAT TTT GCA TTT | 50 | 542 | ||
| MCR-4F | ATT GGG ATA GTC GCC TTT TT | 58 | 487 | ||
| MCR-5-F | ATG CGG TTG TCT GCA TTT ATC | 50 | 1644 | ||
List of primers used for plasmid replicons typing in this study
| Primers | Sequence (5ʹ to 3ʹ) | Target sites/genes | Annealing temperature | Amplicons size | References |
|---|---|---|---|---|---|
| HI1-F | GGAGCGATGGATTACTTCAGTAC | parA-parB | 58 °C | 471-bp | |
| HI2 -F | GGCTCACTACCGTTGTCATCCT | RNAI | 58 °C | 644-bp | |
| I1-F | CGAAAGCCGGACGGCAGAA | iterons | 58 °C | 139-bp | |
| X -F | AACCTTAGAGGCTATTTAAGTTGCTGAT | ori ꭚ | 58 °C | 376-bp | |
| L/M-F | GGATGAAAACTATCAGCATCTGAAG | repA, B, C | 58 °C | 785-bp | |
| N-F | GTCTAACGAGCTTACCGAAG | repA | 58 °C | 559-bp | |
| FIA- F | CCATGCTGGTTCTAGAGAAGGTG | iterons | 58 °C | 462-bp | |
| FIB –F | GGAGTTCTGACACACGATTTTCTG | repA | 58 °C | 702-bp | |
| W-F | CCTAAGAACAACAAAGCCCCCG | repA | 58 °C | 242-bp | |
| Y-F | AATTCAAACAACACTGTGCAGCCTG | repA | 58 °C | 765-bp | |
| CTATGGCCCTGCAAACGCGCCAGAAA | iterons | 58 °C | 534-bp | ||
| FIC –F | GTGAACTGGCAGATGAGGAAGG | repA2 | 58 °C | 262-bp | |
| A/C -F | GAGAACCAAAGACAAAGACCTGGA | repA | 58 °C | 465-bp | |
| T-F | TTGGCCTGTTTGTGCCTAAACCAT | repA | 58 °C | 750-bp | |
| FIIS –F | CTGTCGTAAGCTGATGGC | repA | 58 °C | 270-bp | |
| FrepB-F | TGATCGTTTAAGGAATTTTG | RNAI/repA | 58 °C | 270-bp | |
| K/B -F | GCGGTCCGGAAAGCCAGAAAAC | RNAI | 58 °C | 160 bp | |
| B/O-F | GCGGTCCGGAAAGCCAGAAAAC | RNAI | 58 °C | 159 bp | |
| X4- F | AGCAAACAGGGAAAGGAGAAGACT | - | 62 °C | 569 bp | |
| IncI2-F | ATTGTTGCGTGGCTTCAT | - | 60 °C | 353 bp | This study |
Distribution of MICs of 11 antibiotics for 275 MDR Escherichia coli isolates
| Antibiotics | MIC (mg/L) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.008 | 0.016 | 0.032 | 0.063 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | MIC50 | MIC90 | Resistance | |
| - | - | - | - | - | - | - | 0 | 1 | 1 | 1 | 6 | 4 | 12 | 23 | 38 | 189 | >256 | >256 | 96.72% | |
| - | - | - | 0 | 8 | 9 | 11 | 14 | 18 | 15 | 14 | 19 | 31 | 45 | 44 | 33 | 14 | 32 | 256 | 78.18% | |
| - | - | - | - | 0 | 3 | 2 | 11 | 3 | 1 | 18 | 72 | 51 | 56 | 30 | 9 | 19 | 32 | 128 | 86.18% | |
| - | - | - | - | 0 | 3 | 21 | 23 | 14 | 12 | 26 | 19 | 28 | 33 | 56 | 31 | 9 | 32 | 256 | 77.81% | |
| - | - | - | - | - | - | 0 | 0 | 2 | 1 | 7 | 5 | 17 | 34 | 35 | 61 | 113 | 256 | >256 | 94.54% | |
| - | 0 | 15 | 19 | 5 | 6 | 3 | 14 | 10 | 25 | 26 | 42 | 47 | 38 | 23 | 2 | - | 16 | 64 | 73.81% | |
| - | - | 0 | 9 | 29 | 8 | 14 | 22 | 29 | 110 | 41 | 7 | 4 | 2 | 0 | - | - | 4 | 8 | 70.18% | |
| - | - | - | 0 | 12 | 14 | 9 | 17 | 13 | 4 | 12 | 25 | 54 | 56 | 27 | 16 | 16 | 32 | 256 | 70.54% | |
| 0 | 16 | 158 | 75 | 10 | 4 | 3 | 2 | 3 | 1 | 0 | 0 | 0 | - | - | - | - | 0.032 | 0.0625 | 0.36% | |
| - | - | - | 3 | 12 | 12 | 15 | 37 | 41 | 87 | 49 | 16 | 2 | 1 | 0 | - | - | 4 | 8 | 71.27% | |
| - | - | - | - | - | - | 0 | 3 | 0 | 3 | 0 | 1 | 16 | 41 | 47 | 69 | 96 | 256 | >256 | 97.81% | |
Notes: Red vertical lines indicate the breakpoints between intermediate and resistant values. White areas indicate range of tested dilutions for each antibiotic; the MIC50 and MIC90 values are concentrations at which ≥50% and ≥90% of isolates are inhibited.
Abbreviations: MIC, minimum inhibitory concentration.
Prevalence of mcr-1 & or ESBL-producing E. coli in swine samples collected from different farms of Jiangsu China
| Farm numbers | No. of positive | No. of | No. of |
|---|---|---|---|
| Farm 1 | 32 | 22 (68.7) | 10 (31.2) |
| Farm 2 | 11 | 7 (63.6) | 3 (27.2) |
| Farm 3 | 10 | 8 (80.0) | 4 (40.0) |
| Farm 4 | 26 | 18 (69.2) | 4 (15.3) |
| Farm 5 | 14 | 14 (100) | 2 (14.2) |
| Farm 6 | 14 | 13 (92.8) | 2 (14.2) |
| Farm 7 | 7 | 5 (71.4) | N.D. |
| Farm 8 | 14 | 12 (85.7) | 6 (42.8) |
| Farm 9 | 16 | 14 (87.5) | 9 (56.2) |
| Farm 10 | 43 | 37 (86.0) | 11 (25.5) |
| Farm 11 | 23 | 11 (47.8) | 5 (21.7) |
| Farm 12 | 12 | 9 (75.0) | 6 (50) |
| Farm 13 | 14 | 7 (50.0) | 4 (28.5) |
| Farm 14 | 7 | 7 (100.) | 5 (71.4) |
| Diseased | 32 | 13 (40.6) | 7 (21.8) |
| Total | 275 | 197 | 78 |
Abbreviations: ESBL, extended-spectrum β-lactamase; N.D., not determined.
Distribution of various resistance genes among 275 MDR Escherichia coli isolates from pigs
| Colistin resistant gene | Extended-spectrum beta-lactamase genes | |||
|---|---|---|---|---|
| + | 119 | |||
| 1 | ||||
| + | 34 | |||
| + | 13 | |||
| + | 15 | |||
| + | + | 55 | ||
| + | + | 11 | ||
| + | + | 6 | ||
| + | + | + | + | 1 |
| + | + | + | 4 | |
| + | + | + | 1 | |
| + | + | + | 1 | |
| + | + | 2 | ||
| + | + | 2 | ||
| + | + | 1 | ||
| N.D. | N.D. | N.D. | N.D. | 9 |
| 197 | 100 | 33 | 27 | 275 |
Abbreviations: +, positive; N.D., not determined.
The resistance patterns of E. coli with or without mcr-1
| Resistance profiles | |||
|---|---|---|---|
| ≥11 drugs | 0 (0) | 0.0 (0) | - |
| ≥10 drugs | 68.02 (134) | 0.0 (0) | 0.000 |
| ≥9 drugs | 68.52 (135) | 3.84 (3) | 0.000 |
| ≥8 drugs | 81.21 (160) | 58.97 (46) | 0.000 |
| ≥7 drugs | 89.84 (177) | 76.92 (60) | 0.005 |
| ≥6 drugs | 93.90 (185) | 88.46 (69) | 0.125 |
| ≥5 drugs | 99.49 (196) | 91.02 (71) | 0.000 |
| ≥4 drugs | 100.0 (197) | 93.58 (73) | 0.000 |
| ≥3 drugs | 100.0 (197) | 96.15 (75) | 0.006 |
| ≥2 drugs | 100.0 (197) | 98.71 (77) | 0.111 |
Figure 1Distribution of various resistance genes in combination.
Figure 2Detection of plasmid replicon types in multidrug-resistant E. coli using PCR assay.
Conjugation experiments and plasmid replicon type detection for 15 mcr-1-positive E. coli
| Strain | CTX | COL | Plasmid (Inc) | Resistance genes | Resistance profile for non-beta-lactam antibiotics |
|---|---|---|---|---|---|
| EC-9 | 128 | 16 | HI2,I1,Y, FIC | MCR-1, CTX-M-15 | GEN, ENR, NAL, SUL, CIP, KEN, CHL, TET, TRM, STR,POL-B |
| EC-9-T | 128 | 4 | HI2, FIC | MCR-1, CTX-M-15 | GEN, ENR, NAL, SUL, KEN, CHL, TET, TRM, POL-B |
| EC-37 | 256 | 8 | N, P | MCR-1, CTX-M-55 | NAL, SUL, CFX, CEF, KEN, CHL, TET, TRM, STR, POL-B |
| EC-37-T | 32 | 4 | N | MCR-1, CTX-M-55 | NAL, SUL, CFX, CEF, KEN, CHL, TET, TRM, STR, POL-B |
| EC-48 | 256 | 4 | FIB, P, FrepB, N | MCR-1, CTX-M-55 | GEN, ENR, NAL, SUL, KEN, CHL, TET, TRM, STR,POL-B |
| EC-48-T | 32 | 2 | FIB, N | MCR-1, CTX-M-55 | GEN, ENR, NAL, SUL, KEN, CHL, TET, TRM, STR,POL-B |
| EC-52 | 128 | 4 | FIB,N, P | MCR-1, CTX-M-55 | ENR, NAL, SUL, CEF, KEN, CHL, TET, TRM, STR,POL-B |
| EC-52-T | 256 | 2 | FIB,N | MCR-1, CTX-M-55 | ENR, NAL, SUL, CEF, KEN, CHL, TET, TRM, STR |
| EC-29 | 256 | 8 | HI2, FIB | MCR-1, CTX-M-15 | GEN, NAL, SUL, CFX, CEF, KEN, CHL, TET, TRM, STR,POL-B |
| EC-29-T | 0.5 | 2 | HI2, FIB | MCR-1, CTX-M-15 | GEN, NAL, SUL, KEN, CHL, TET, TRM, POL-B |
| EC-34 | 256 | 8 | FIB, HI2, FrepB | MCR-1, CTX-M-15 | GEN, NAL, SUL, CEF, KEN, CHL, TET, TRM, STR,POL-B |
| EC-34-T | >256 | 8 | HI2,FIB | MCR-1, CTX-M-15 | GEN, NAL, SUL, CEF, KEN, CHL, TET, TRM, POL-B |
| EC-40 | 128 | 4 | HI2, FIB, FrepB | MCR-1, CTX-M-15 | ENR, NAL, SUL, CFX, CEF, CIP, KEN, CHL, TET, TRM, POL-B |
| EC-40-T | 64 | 2 | HI2, FIB | MCR-1, CTX-M-15 | ENR, NAL, SUL, CFX, CEF, KEN, CHL, TET, TRM, POL-B |
| EC-1 | 256 | 4 | X4, FIC | MCR-1, TEM | GEN, ENR, NAL, SUL, CIP, KEN, CHL, TET, TRM, STR, POL-B |
| EC-1-T | 256 | 2 | X4, FIC | MCR-1, TEM | GEN, NAL, SUL, CEF, CIP, KEN, CHL, TET, TRM, STR, POL-B |
| EC-2SF | 256 | 2 | HI2,FIB, P | MCR-1, CTX-M-15 | GEN, ENR, NAL, SUL, CIP, KEN, CHL, TET, TRM, STR,POL-B |
| EC-2SF-T | >256 | 4 | HI2, FIB | MCR-1, CTX-M-15 | ENR, NAL, SUL, CIP, KEN, CHL, TET, TRM, STR,POL-B |
| EC-55 | 64 | 8 | HI2,FIB, FIC,Y | MCR-1, CTX-M-55 | ENR, NAL, SUL, CIP, KEN, CHL, TET, TRM, STR,POL-B |
| EC-55-T | 64 | 4 | HI2,FIC | MCR-1, CTX-M-55 | ENR, NAL, SUL, CIP, KEN, CHL, TET, TRM, POL-B, STR |
| EC-20 | 2 | 4 | X4, FIC, FrepB | MCR-1 | GEN, ENR, NAL, SUL, CIP, KEN, CHL, TET, TRM, POL-B |
| EC-20-T | 0.25 | 4 | X4, FIC | MCR-1 | GEN, NAL, SUL, KEN, CHL, TET, TRM, STR,POL-B |
| EC-19 | 128 | 32 | HI2 | MCR-1 | GEN, NAL, SUL, CIP, KEN, CHL, TET, TRM, POL-B |
| EC-19-T | 256 | 4 | HI2 | MCR-1 | GEN, NAL, SUL, KEN, CHL, TET, TRM, POL-B |
| EC-600 | 0.25 | 0.125 | ND | ND |
Abbreviations: COL, colistin; CTX, cefotaxime; GEN, gentamycin; ENR, enrofloxacin; NAL, nalidix-acid; SUL, sulfamethaxozole; CIP, ciprofloxacin; KEN, kenamycin; CHL, chloramphenicol; TET, tetracycline; TRM, trimethropim; STR, streptomycin; POL-B, polymyxin-B; ND, not determined.
Figure 3(A) S1-nuclease pulsed-field gel electrophoresis profiles of six E. coli and (B) Southern Blot hybridization of six E. coli carrying the mcr-1 plasmid.
Notes: M – Salmonella H9812 (15.0–242.5 kb); 1: E-55; 2: E-01; 3: E-09; 4: E-02; 5: E-44; and 6: E-37. The arrows in the figure represent the position of the mcr-1 plasmid.